Anhedonia
83
20
23
45
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Published Results
16 trials with published results (19%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
3.6%
3 terminated out of 83 trials
93.8%
+7.2% vs benchmark
13%
11 trials in Phase 3/4
36%
16 of 45 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 45 completed trials
Clinical Trials (83)
Investigating the Efficacy and Mechanisms of Individualized tACS Targeting Anhedonia in Late-Life Depression
A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure
Get ActivE Study for At-risk Youth
Multimodal Differences in Effort-based Decision-Making in Depression
Inflammation and Depression in People With HIV
Psilocybin as a Novel Therapy for Residual Anhedonia
Psilocybin for Treatment-Resistant Depression
Geolocation Positional System (GPS) Experience
The Effect of Transcranial Direct Current Stimulation (tDCS) in Improving Emotion Health
Psychotherapy Effects on Reward Processing in PTSD
Long-term Follow-up of Depressive Disorders in Psychiatric Care
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
Long-term Efficacy of Pramipexole in Anhedonic Depression
Pramipexole for Anhedonic Depression
PD, PK, and Safety of ALTO-203 in Patients With MDD
Reward Processing and Exposure Therapy for Social Anxiety Disorder
Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression
Positive Affect Treatment for Spanish-Speaking Individuals
Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects
Anhedonia, Development, and Emotions: Phenotyping and Therapeutics